Premium
Cognitive profiles and response to donepezil treatment in Alzheimer's disease patients
Author(s) -
Shimizu Soichiro,
Hanyu Haruo,
Sakurai Hirofumi,
Iwamoto Toshihiko,
Takasaki Masaru
Publication year - 2006
Publication title -
geriatrics and gerontology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 57
eISSN - 1447-0594
pISSN - 1444-1586
DOI - 10.1111/j.1447-0594.2006.00328.x
Subject(s) - donepezil , neuropsychology , medicine , cognition , alzheimer's disease , mini–mental state examination , dementia , disease , audiology , psychiatry
Background: The aim of this study was to determine whether there are certain characteristic neuropsychological profiles, assessed by the Mini‐Mental State Examination (MMSE) at baseline, which predict donepezil treatment response. Methods: A total of 112 consecutive outpatients with Alzheimer's disease (AD) were treated with donepezil for 3–4 months. Multiple regression analysis was performed to estimate the relative contributions of individual subscales at baseline to the MMSE change (study point – baseline). To identify the characteristic patterns in cognitive deficits of patients with AD who responded to donepezil therapy, the subscales of the MMSE at baseline of responders and non‐responders were compared. Results: Multiple regression analysis revealed that lower scores on attention and calculation, and language function, and a higher scale on orientation (date) are related to an improvement of the MMSE. When an improvement of 4 or more points on the MMSE score was defined as a significant response, responders scored significantly lower than non‐responders on attention and calculation, whereas non‐responders scored significantly lower than responders on memory. Conclusion: Our results suggest that individual differences in patterns of neuropsychological impairments may partly contribute to the diversity of the response to donepezil treatment. Although further studies with more detailed neuropsychological tests are needed to confirm our results, the MMSE may add to the prediction of response to donepezil treatment in patients with AD.